The PCSK9[Biotinylated]-LDLR Binding Assay Kit is designed for screening and profiling purposes. PCSK9 is known to function as a negative regulator of hepatic low-density lipoprotein receptors (LDLRs) by binding to the LDLR ectodomain. The key to this kit is the high sensitivity of detection of biotin-labeled PCSK9 by streptavidin-HRP. Only a few steps are required for the assay. First, LDLR ectodomain is coated on a 96-well plate. Next, PCSK9 is incubated with LDLR on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, measured using a chemiluminescence reader.

*NOTE: As of November 2022, this protocol has been re-optimized for performance. Previous versions of this kit are available upon request.

This product has been cited 5 times.